SAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company Oct 25, 2021 07:39AM
SAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company Oct 25, 2021 07:39AM
Big Cypress Acquisition (BCYP) Stockholders Approve Business Combination with SAB Biotherapeutics Oct 21, 2021 07:04AM
Big Cypress Acquisition Corp. Stockholders Approve Business Combination with SAB Biotherapeutics Oct 21, 2021 07:00AM
SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021 Oct 6, 2021 07:00AM


Oct 4, 2021 07:00AM SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19
Sep 28, 2021 07:00AM SAB Biotherapeutics Appoints Russell Beyer Chief Financial Officer
Sep 24, 2021 07:01AM SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19 (BCYP)
Sep 24, 2021 07:00AM SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19
Sep 23, 2021 07:00AM Big Cypress Acquisition Corp Announces Special Meeting of Stockholders to Approve Business Combination with SAB Biotherapeutics
Sep 22, 2021 07:03AM Big Cypress Acquisition (BCYP) and SAB Biotherapeutics Awarded Additional $60.5M from BARDA and US DoD for Rapid Response Capability and Advancing SAB-185 for Treatment of COVID-19
Sep 22, 2021 07:00AM SAB Biotherapeutics Awarded Additional $60.5M from BARDA and U.S. Department of Defense for Rapid Response Capability and Advancing SAB-185 for Treatment of COVID-19
Sep 15, 2021 07:00AM SAB Biotherapeutics Announces Completion of Enrollment in Phase 2a Challenge Trial of SAB-176 for the Treatment of Seasonal Influenza
Sep 8, 2021 07:00AM SAB Biotherapeutics to Present at Upcoming September Virtual Investor Conferences
Aug 11, 2021 07:02AM SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda SARS-CoV-2 Variants (BCYP)
Aug 11, 2021 07:00AM SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda SARS-CoV-2 Variants
Jul 15, 2021 07:00AM Big Cypress Acquisition Corp. Reports Ladenburg Conference Presentation by Planned Merger Partner SAB Biotherapeutics
Jul 9, 2021 07:00AM SAB Biotherapeutics to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021
Jul 8, 2021 05:14PM SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS-CoV-2 Variants (BCYP)
Jul 8, 2021 07:06AM SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS-CoV-2 Variants
Jul 8, 2021 07:06AM SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS-CoV-2 Variants
Jul 7, 2021 07:00AM Big Cypress Acquisition Corp. Announces Confidential Submission of S-4 Registration Statement Related to Proposed Business Combination with SAB Biotherapeutics
Jul 2, 2021 07:47AM SAB Biotherapeutics Doses First Participant in Phase 2a Trial of SAB-176 for the Treatment of Influenza
Jun 29, 2021 07:00AM SAB Biotherapeutics Doses First Participant in Phase 2a Trial of SAB-176 for the Treatment of Influenza
Jun 22, 2021 06:23AM SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition (BCYP)
Jun 22, 2021 06:00AM SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp., Advancing Unique Human Antibody Platform with Demonstrated Utility in Immunotherapy and Rapid Response to Emerg
Feb 23, 2016 07:00AM Blue Calypso Deploys Its KIOSentrix® Platform Across Four Thousand US Retail Locations and Twenty Thousand Products
Sep 29, 2015 07:00AM Dallas-Based Blue Calypso and TeamConnor Partner to Fight Childhood Cancer at Color Me Green 5K and Caterpillar Dash Event
Mar 27, 2014 07:05AM Blue Calypso Teams With the Association of Network Marketing Professionals to Promote International Convention in Dallas, March 27-30